30,000 Shares in NewAmsterdam Pharma Company N.V. $NAMS Acquired by Ishara Investments LP

Ishara Investments LP bought a new position in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 30,000 shares of the company’s stock, valued at approximately $1,052,000. NewAmsterdam Pharma comprises approximately 1.2% of Ishara Investments LP’s portfolio, making the stock its 28th largest position.

Several other hedge funds have also modified their holdings of NAMS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of NewAmsterdam Pharma in the first quarter worth approximately $610,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in NewAmsterdam Pharma by 13.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 288,134 shares of the company’s stock valued at $5,898,000 after acquiring an additional 34,563 shares during the last quarter. Geode Capital Management LLC boosted its holdings in NewAmsterdam Pharma by 15.9% in the second quarter. Geode Capital Management LLC now owns 99,457 shares of the company’s stock valued at $1,800,000 after acquiring an additional 13,629 shares during the last quarter. Legal & General Group Plc boosted its holdings in NewAmsterdam Pharma by 33.5% in the second quarter. Legal & General Group Plc now owns 44,235 shares of the company’s stock valued at $801,000 after acquiring an additional 11,106 shares during the last quarter. Finally, Invesco Ltd. boosted its holdings in NewAmsterdam Pharma by 12.7% in the second quarter. Invesco Ltd. now owns 134,035 shares of the company’s stock valued at $2,427,000 after acquiring an additional 15,101 shares during the last quarter. 89.89% of the stock is owned by institutional investors and hedge funds.

Insider Activity at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 65,000 shares of the business’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $35.69, for a total transaction of $2,319,850.00. Following the transaction, the chief accounting officer owned 24,353 shares in the company, valued at $869,158.57. The trade was a 72.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 12.74% of the stock is currently owned by corporate insiders.

NewAmsterdam Pharma Price Performance

Shares of NAMS opened at $30.15 on Thursday. The stock’s 50-day moving average is $33.26 and its two-hundred day moving average is $33.42. The stock has a market cap of $3.52 billion, a PE ratio of -16.84 and a beta of 0.07. NewAmsterdam Pharma Company N.V. has a 12 month low of $17.63 and a 12 month high of $42.21.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its quarterly earnings data on Tuesday, March 31st. The company reported ($0.40) EPS for the quarter. The company had revenue of $3.04 million for the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%. On average, research analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.78 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on NAMS shares. Truist Financial started coverage on NewAmsterdam Pharma in a report on Wednesday, March 18th. They issued a “buy” rating and a $57.00 target price on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of NewAmsterdam Pharma in a report on Thursday, February 19th. Wall Street Zen upgraded NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Guggenheim lifted their target price on NewAmsterdam Pharma from $41.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, February 19th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $48.60.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical?stage biopharmaceutical company focused on discovering and developing novel small?molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small?molecule candidates at various stages of preclinical and clinical evaluation.